Skip to main content

A picture of a syringue and two flasks of Pandemrix A (H1N1) vaccine from Glaxo Smith Kline.

JEAN-PIERRE MULLER

The federal government has announced a new 10-year pandemic flu vaccine contract with GlaxoSmithKline, valued at more than $425-million.

The contract is intended to ensure a secure supply of vaccine for Canadians in the event of a future influenza pandemic and reduce the possibility of delays in delivery and distribution.

The vaccine will be made at the company's facility in Ste-Foy, Que.

Story continues below advertisement

And this time around, the government has also signed a three-year contract with Sanofi Pasteur Ltd. of Toronto to provide access to a back-up supply of pandemic vaccine if needed.

That contract is worth just over $33-million and would provide an alternate source of vaccine to treat vulnerable populations, such as pregnant women and those suffering from chronic diseases.

The government says the two contracts, along with a three-year deal with Novartis worth almost $50-million, will also provide the provinces and territories with seasonal flu vaccine for their annual flu shot campaigns.

"We have worked with our provincial and territorial counterparts to provide governments with a broader range of vaccine products for seasonal flu and to deliver on the commitment to have a long-term pandemic vaccine contract in place before the current contract expires on March 31, 2011," Health Minister Leona Aglukkaq said in a statement Friday.

"Our new primary pandemic vaccine supply contract provides timely, cost-effective access to a secure domestic supply of vaccine for Canadians in the event of an influenza pandemic."

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.